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Abstract
Background: Idiopathic congenital talipes equinovarus (ICTEV) is a congenital limb deformity.
Based on extended transmission disequilibrium testing, Gli-Kruppel family member 3 (Gli3) has been
identified as a candidate gene for ICTEV. Here, we verify the role of Gli3 in ICTEV development.
Methods: Using the rat ICTEV model, we analyzed the differences in Gli3 expression levels
between model rats and normal control rats. We used luciferase reporter gene assays and ChIP/
EMSA assays to analyze the regulatory elements of Gli3.
Results: Gli3 showed higher expression levels in ICTEV model rats compared to controls (P <
0.05). We identified repressor and activator regions in the rat Gli3 promoter. The Gli3 promoter
also contains two putative Hoxd13 binding sites. Using EMSA, the Hoxd13 binding site 2 was found
to directly interact with Hoxd13 in vitro. ChIP assays of the Hoxd13-Gli3 promoter complex from
a developing limb confirmed that endogenous Hoxd13 interacts with this region in vivo.
Conclusion: Our findings suggest that HoxD13 directly interacts with the promoter of Gli3. The
increase of Gli3 expression in ICTEV model animal might result from the low expression of
HoxD13.
Background
Idiopathic congenital talipes equinovarus (ICTEV) is a
congenital limb deformity that affects 0.3-7% of live
births worldwide [1]. It is defined by fixation of the foot
in cavus, adductus, varus and equinus (inclined inwards,
axially rotated outwards and pointing downwards) with
related soft tissue abnormalities [2]. The mechanism
underlying the development of ICTEV remains unclear,
and neurological, muscular, bony, connective tissue and
vascular mechanisms have all been proposed as contribut-
ing factors [2-5]. Although some studies have suggested
that both genetic and environmental factors lead to
ICTEV, twin studies, ethnic studies and pedigree analyses
suggest a genetic basis for the condition [6]. Furthermore,
studies have suggested that a significant ICTEV risk can be
attributed to unknown disorder-causing genes [1]. Over-
all, little is known about the pathogenesis of human
ICTEV.
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posed because the molecular and cellular components of
vertebrate limb bud development are well known. Spe-
cialized regions of the developing limb bud, such as the
zone of polarizing activity (ZPA), the apical ectodermal
ridge (AER) and the non-ridge ectoderm, direct and coor-
dinate the development of the limb bud along the ante-
rior-posterior (AP), dorsal-ventral (DV) and proximal-
distal (PD) axes in a pattern conserved for tetrapods [7].
Distal limb development along the AP (thumb to little
finger) axis is governed primarily by the ZPA. The major
signaling molecule with polarizing potential in the ZPA is
Sonic hedgehog (Shh) [8], which plays a central role in
pattern formation in the embryo [9] and is a key signal in
establishing different digit fates along the AP axis of the
vertebrate limb bud [10]. In Drosophila, hedgehog (Hh)
signaling is mediated by the Cubitus interruptus (Ci) pro-
tein, a zinc finger transcription factor. In birds and mam-
mals, Ci homologs constitute the three member Gli family
(Gli1, Gli2, and Gli3). All three Gli genes are expressed in
the developing limb, but only Gli3, a direct intracellular
mediator of Shh [11-13], is necessary for limb patterning
[14,15]. With a C-terminal repressor region and an N-ter-
minal activator region, Gli3 is a bipotential transcription
factor that can activate or repress some of the same target
genes [16]. During vertebrate limb development, Shh sig-
naling prevents the processing of the full-length Gli3
(Gli3-190) to a short form (Gli3-83) that functions as a
strong repressor. In both mouse and chick limb buds, the
repressor form of Gli3 is present in an anterior-posterior
gradient with the highest levels in the anterior part of the
limb bud where Shh signaling is at its lowest levels. The
genetic data of the Shh, Gli3 and double-compound
mutants indicate that the phenotype in the absence of Shh
is caused by an excess in the Gli3R form that suppresses
gene expression, cell survival and distal progression of
limb bud development. Gli3 and Shh reciprocally restrict
each other to control the normal limb morphogenesis
[17].
A third family of transcription factors involved in limb
development is the HOX family, which is evolutionarily
conserved and plays a fundamental role in patterning the
AP axis of developing embryos. Each HOX protein medi-
ates cellular events during limb morphogenesis [18,19].
The physical position of the Hox gene within each cluster
corresponds closely to their temporal and spatial expres-
sion patterns during development. Thus, genes at the 3'
end of the clusters, such as HOXD1, are expressed early in
the anterior and proximal regions, whereas genes at the 5'
end, such as HOXD13, are expressed later in posterior and
distal regions [20]. In early limb bud development, the
Gli3 anterior expression overlaps the HoxD posterior
expression, indicating that a genetic interaction between a
5' HoxD member and Gli3 regulates digit formation [21].
Biochemical and transfection analyses provide support for
the physical interaction of the 5' HoxD protein and Gli3
protein via the homeodomain [21]. This interaction can
convert the truncated Gli3 repressor form into an activator
of its target promoters [21].
Most Gli3 research focuses on digit abnormalities and
deformities. Gli3 mutations cause limb development dis-
orders, such as Greig cephalopolysyndactyly syndrome
(GCPS) [22], Pallister-Hall syndrome (PHS) [23], postax-
ial polydactyly type A (PAP-A) [24] and preaxial polydac-
tyly type IV [25]. Association analyses suggest that Gli3
and HoxD13 are associated with ICTEV [26-28]. To con-
firm a role for Gli3 in ICTEV, we analyzed Gli3 expression
in ICTEV model rat embryos. To understand how a change
in the expression of Gli3 affects ICTEV, we investigated the
interaction between Gli3 and HoxD13.
Methods
ICTEV patients and normal controls
Flexor hallucis longus was from 20 ICTEV patients (13
men and 7 women) aged 4-12 years (mean 6.7 years) and
peripheral blood was from 84 ICTEV patients (50 men
and 34 women) aged 3-12 years (mean 6.2 years). All
patients were recruited from the Department of Pediatric
Orthopedic Surgery, Second Affiliated Hospital of China
Medical University. Informed consent was obtained from
the patients and the study was approved by the China
Medical University Ethics Committee. The probands
showed the typical ICTEV phenotype (a fixation of the
foot in adduction, supination and varus). Flexor hallucis
longus and lung tissue were from nine normal cadavers (5
men and 4 women) aged 5-11 years (mean 7.5 years) as
controls.
A rat ICTEV model
Forty pregnant Wistar rats were obtained from the experi-
mental animal center of our university. The ICTEV pheno-
type in rat embryos was induced by administration of 135
mg/kg all-trans-retinoic acid (ATRA) on gestation day 10
(GD10), as previously described [29,30]. All studies were
performed with the approval of the experimental animal
committee at our university (SCXK 2008-0005).
RNA isolation and expression analysis
The Gli3 gene is expressed as an 8.5 kb mRNA in tissues
such as the postnatal testis, myometrium, placenta and
lung [31]. We investigated whether the gene was also
expressed in the hindlimb. RNA was therefore extracted
from the flexor hallucis longus of ICTEV patients and nor-
mal controls using a Tissue RNA kit (Tiangen, China)
according to the manufacturer's protocol. RNA was also
extracted from lung tissues of normal cadavers as a posi-
tive control. Using a reverse transcription kit (Promega,
USA) according to the manufacturer's instructions, cDNAPage 2 of 10
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were 5'-TTT TCC AAC ACA GAG GCC TAT TC-3' and 5'-
ATC TTG GAC CTC TTG TTG TGC AT-3', respectively.
Human β-actin forward and reverse primers were 5'-TCA
CCC ACA CTG TGC CCA TCT ACG A-3' and 5'-CAG CGG
AAC CGC TCA TTG CCA ATG G-3', respectively. PCR reac-
tions contained 40 ng cDNA, 1.2 mM MgCl2, 20 mM
dNTPs, 320 nM of each primer and 2U Taq polymerase in
a 25 μl total volume. PCR reactions had an initial denatur-
ing step at 94°C for 5 minutes, followed by 35 cycles of
denaturing at 94°C for 45 sec, annealing at 58°C for 45
sec and extension at 72°C for 60 sec, and ended with a
final extension at 72°C for 10 min.
Gli3 expression in ICTEV rat models and normal control 
rats
Real-time PCR (RT-PCR) was performed to evaluate differ-
ences in RNA expression levels. The ICTEV model rats
were dissected at GD15, GD17, GD19 and GD21. Five
embryos with clubfoot were selected and the hindlimbs of
the embryos were stored at -70°C. We also dissected con-
trol rats at GD15, GD17, GD19 and GD21 and five
embryos were selected and their hindlimbs were similarly
stored. RNA was extracted from the hindlimbs using a Tis-
sue RNA kit (Tiangen, China) and cDNA was synthesized
using a reverse transcription kit (Promega, USA) accord-
ing to the manufacturer's instructions. Real-time PCR
amplification was performed in a 25 μl reaction mixture,
which included 12.5 μl SYBR Premix Ex Taq, 9.5 μl deion-
ized water, 0.5 μl (initial concentration 10 μM) of each
primer and 2 μl cDNA, according to the manufacturer's
instructions (Takara Biotechnology). Amplification was
performed by one round of pre-denaturation at 95°C for
10 s, a step-cycle mode of 40 rounds of denaturation at
95°C for 5 s and an annealing and extension step at 58°C
for 20 s. The primers used for Gli3 were: forward: 5'-TTT
TCC AAC ACA GAG GCC TAT TC-3' and reverse: 5'-ATG
CAC AAC AAG AGG TCC AAG AT-3'. The primers of β-
actin were: forward: 5'-TCC TTC CTG GGT ATG GAA TC-
3' and reverse: 5'-GCA CTG TGT TGG CAT AGA GG-3'.
To evaluate Gli3 protein expression level, we performed
western blot analyses. Cytoplasmic protein was extracted
from the embryonic hindlimbs of five rats presenting with
clubfoot and normal control rat embryonic hindlimbs at
GD15 and GD17 using a cytoplasmic and nuclear protein
extract kit (Activ Motif, USA) according to the manufac-
turer's instructions. Protein concentration was deter-
mined spectrophotometrically (Unico, USA) at 280
nm[32]. Sample buffer (Beyotime, China) was added to
the cytoplasmic protein and the solution was loaded onto
a 6% polyacrylamide gel. Following protein separation,
the polyacrylamide gel was electro-blotted onto a PVDF
membrane (Millipore, MA, USA). Non-specific binding
sites were blocked by soaking the membrane in a 3% BSA
(Sigma, Poole, Dorset, UK) in TBST buffer (20 mM Tris-
buffered saline, 0.047% Tween at pH 7.4) blocking solu-
tion overnight at 4°C. The membrane was incubated for 3
hours with rabbit anti-human Gli3 polyclonal antibody
(Santa Cruz, USA, 1:50 dilution) at room temperature and
washed for 40 min in TBST buffer. The membrane was
then incubated for 2 hours at room temperature with a
goat anti-rabbit IgG horseradish peroxidase-conjugated
antibody (Antibodies Incorporated, USA. 1:4000 dilu-
tion). Protein bands were visualized using modified
enhanced chemiluminescence (Tiangen, China).
To determine differences in Gli3 levels and localization,
we used immunohistochemistry assays. The ICTEV model
rats and control rats were dissected at GD19. We selected
five embryos presenting with clubfoot from the ICTEV rats
and five normal embryos from normal control rats. The
hindlimbs of the embryos were embedded in paraffin and
fixed in 4% paraformaldehyde overnight at 4°C. The tis-
sues were sectioned into 4-μm slices and labeled with Gli3
antibody (Santa Cruz, USA, 1:50 dilution). The normal
control hindlimbs were labeled with Phosphate buffered
saline as negative controls. A standard immunohisto-
chemistry protocol was used (Maxim Biotech, Inc., USA).
Gli3 mutation analysis
Genomic DNA was extracted from 84 fresh blood samples
obtained from the ICTEV patients using a Blood DNA kit
(Tiangen, China) according to the manufacturer's proto-
col. A previous study investigated mutations in Gli3 exons
9, 10, 11 and 12 [26]. We therefore designed primers
(shown in Table 1) to amplify the remaining Gli3 exons 1-
8, 13 and 14 and the 5' flanking sequence. Mutations in
Gli3 were detected by denaturing gradient gel electro-
phoresis (DGGE), a sensitive method to separate alleles
based on differences in melting behavior [33].
Identification of the rat Gli3 promoter
To obtain a candidate rat Gli3 promoter sequence, four
forward primers were designed upstream of the rat Gli3:
Gli3(-1107), 5'-GTG ACC TGC CTG TGC CTG TA-3';
Gli3(-532), 5'-TTA ACC TCT GCG TTA CAA CC-3'; Gli3(-
388), 5'-ATC AGA GGG TCT CAG CGT TAG-3'; and Gli3(-
128), 5'-CTC CTC AGG CAG AAG ATG CA -3'. Four prod-
ucts were obtained when rat genomic DNA was amplified
with each of these primers and the Gli3 reverse primer 5'-
ACA CCA CAG TGC CAT CAA A -3'. The amplified frag-
ments were verified by sequencing and cloned into a
PMD-18T vector. The clones were digested with KpnI and
HindIII and cloned into the KpnI and HindIII sites of the
pGL3-luciferase vector (Promega, USA).
L6GNR4 rat myoblastocytes (Cell Laboratory, Chinese
Academy of Sciences, Shanghai) were cultured in Dul-
becco's Modified Eagle's Medium supplemented withPage 3 of 10
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streptomycin and then incubated in 5% CO2 at 37°C. L6
cells were transfected using a liposome transfection kit
(Invitrogen, USA). In each transfection, 12 μg reporter
plasmid and 0.1 μg pRL-TK (internal control for transfec-
tion efficiency) were used per 6-cm dish. Cells were incu-
bated for 48 hours at 37°C. After transfection, the cells
were washed with PBS, lysed with 1× passive lysis buffer
and assayed for luciferase activity using the Dual-Luci-
ferase Reporter Assay System (Promega, USA).
Analysis of the rat Gli3 5' region
To search for regulatory elements in the Gli3 transcrip-
tional control regions, we analyzed the genomic sequence
1000 bp upstream of the transcription start site using P-
Match http://www.gene-regulation.com.
Chromatin immunoprecipitation assays (ChIP)
ChIP assays were performed according to the manufac-
turer's instructions (Active Motif, USA). Hindlimbs of
GD14 rats were homogenized in PBS on ice. Hoxd13 anti-
body (8 μg) (Santa Cruz, USA) was used for the immuno-
precipitation, and 8 μg of the Sox9 antibody (Santa Cruz,
USA) was used as a negative control. DNA was extracted
as recommended by protocol. We used 2.5 μL of each
sample as a template for PCR using the following primers:
Gli3 Site1: ACACTGAGGGCCCTGGGTAG
Table 1: Gli3 primers for DGGE
Primer sequence Annealing Temp (°C) Product size (bp)
Promoter 1 F *AGCTTGCAGTTCCCTTGC 60 684
R GTCCGACAATTTCTAACATCGA
Promoter 2 F *GCCTTCGATGTTAGAAATTGTCG 62 668
R TGGGCTGCTGGTAATCCCTGTGC
Exon 1 F *TTTTGGAAAGTTGATGGCTCT 60 229
R GGCTGCTGGTAATCCCTGT
Exon 2 F *AATTGCTCCTTAAAGTAGTT 60 335
R CATAGCTCCTGAACAAGTG
Exon 3 F *CAATGTTGCTTTGTGAAT 60 234
R TAAAAGCCAGCATCTCGT
Exon 4 F *CCCCTTGTATCTGGTTTT 57 316
R GTCTACTTTATACACGTCCC
Exon5 F *ATTGCTGATGTGGGTTGT 60 297
R GTTGCCTTTGCCATTTCC
Exon 6 F *TAGGCAAGTAGCAATAAATAG 60 303
R ACATAATGGATTCAGGAAAA
Exon 7 F *GCTCAGCGTTTAAGTGAT 61 268
R GCATCGACCTGTCCCTCT
Exon 8 F *GGGATTGGAGAATTATCAG 60 299
R AGTCTTGGGAGGAGTGGG
Exon13 F *TTCCTTTCCACTTGACCCC 60 391
R AAAACCCTGAGCAGATGCA
Exon 14-1 F *TGTGAGGCAGGCAATGTG 53 325
R GGAGAAGCAGGGCGAGAT
Exon 14-2 F *ATCTCGCCCTGCTTCTCC 55 489
R GCTGCTGAGGCTGCTGAA
Exon 14-3 F *AGAGGATGAGCCTGAAGACG 56 486
R GCTGCTCGTACCCTGCTT
Exon 14-4 F *CTGATGCCAACCTGAACG 56 479
R TCCACTGGTGCCACTTCC
Exon 14-5 F *TGGTCGTCCACCCGCAGAA 58 490
R GGCCCTTGGTAGATGTTGATGT
Exon 14-6 F *AGATGCTTGGGCAGATTAG 60 350
R TGAACCAGCTTTCGTGTC
Exon 14-7 F *CGCTGTGCTCTAATCTGC 60 491
R TATTGATTTCCGTTGGTTG
*GC clamp was added at the 5' end of the forward primers
GC clamp: cgcccgccgcgccccgcgcccggcccgccgcccccgcccgPage 4 of 10
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Gli3 Site2: AACCCTTTCGGCACACTTCTG
Gli3 Site2 rev: GTGGCTCTCAACCTTCCTAACG
PCR reactions had an initial denaturing step at 94°C for 5
minutes, followed by 35 cycles of denaturing at 94°C for
35 sec, annealing at 59°C for 35 sec and extension at
72°C for 35 sec, and ended with a final extension at 72°C
for 10 min.
Electrophoretic mobility shift assays (EMSA)
Nucleoprotein was extracted from E14.5 rat embryo limbs
using a cytoplasmic and nuclear protein extract kit (Activ
Motif, USA) according to the manufacturer's instructions
Oligonucleotides and their complementary strands were
used to evaluate binding of HoxD13 to the Gli3 HoxD13-
binding site (5'-CTAGG-3'). The double-stranded wild-
type (tttacaCTAGGattcataaccatagcataattacagcta) and
mutated (tttacaGCTAAattcataaccatagcataattacagcta)
sequences were labeled with biotin according to standard
protocols (Pierce, USA). A 100-fold excess of unlabeled
probe was used as a specific competitor. The DNA-bind-
ing ability of the different proteins was monitored by
EMSA on a 10% non-denaturing polyacrylamide gel. DNA
binding bands were detected using a chemiluminescence
system (Pierce, USA).
Results
Gli3 is not expressed in the flexor hallucis longus of ICTEV 
patients
To investigate the expression profiles of Gli3 in flexor hal-
lucis longus, Semi-quantitative RT-PCR was performed
using total RNA from the flexor hallucis longus of patients
and cadavers as well as the lung tissues of cadavers. No
Gli3 expression was detected in the flexor hallucis longus;
however, expression was detected in control lung tissue
(Fig. 1).
Identification of rat ICTEV model
The embryos were harvested from ATRA-treated pregnant
rats at GD15, 17, 19 and 21. We found embryos with club-
foot at GD15. A comparison between ICTEV and normal
embryos at GD 21 is shown in Fig 2. Hind limb abnormal-
ity was observed in embryos of the ICTEV model rat, sim-
ilar to that seen in ICTEV patients. A total of 74 embryos
with clubfoot were found out of 245 embryos (30.2%),
indicating that the ICTEV model was successfully estab-
lished.
ICTEV association with Gli3 is not due to genetic 
mutations
Unlike other disorders associated with Gli3, no mutations
were observed in the 5' flanking sequence or in Gli3 exons
1-8, 13 and 14 in the ICTEV patients.
Gli3 has higher expression in ICTEV model rats than in 
control rats
To study Gli3 earlier in development, we used a rat model
for ICTEV. Expression of Gli3 was higher in ICTEV model
rat embryonic hindlimbs compared to normal control rat
embryonic hindlimbs (Fig. 3). Similarly, Gli3 protein
showed increased abundance in ICTEV model rat embry-
onic hindlimbs compared to normal control rat embryos
(Fig. 4). For both ICTEV model rats and normal control
rats, Gli3 RNA levels and Gli3 protein abundance
decreased during embryonic development (Figs. 3 and 4).
Semi-quantitative RT-PCR analysis of Gli3 mRNA expression in flexor hallucis longus and lung tissueFigure 1
Semi-quantitative RT-PCR analysis of Gli3 mRNA 
expression in flexor hallucis longus and lung tissue. 
Gli3 expression was not found in the flexor hallucis longus. 
Lanes 1 is an RT-PCR sample from an ICTEV patient flexor 
hallucis longus, lane 2 is a normal control flexor hallucis lon-
gus RT-PCR and lane 3 is a normal control lung RT-PCR. β-
actin expression is shown as a control for all samples. Lane M 
is a size marker.
Comparison of ICTEV and normal embryos at GD21Figure 2
Comparison of ICTEV and normal embryos at GD21. 
(A) Foot of an ICTEV patient, showing cavus, adductus, varus 
and equines. (B) The hindlimbs of normal embryos at GD21 
presented with normal development. (C) The hindlimbs of 
ICTEV embryos at GD21 presented with dysplasia of the 
foot, showing cavus and adductus as observed in ICTEV 
patients.Page 5 of 10
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rats was localized to the foot muscle of the rats (Fig. 5).
Gli3 promoter identification
To determine the promoter region of Gli3, we generated
four luciferase reporter constructs (Luc1107, Luc532,
Luc388 and Luc128) with fragments upstream of Gli3 as
the promoters. All the luciferase reporter constructs
showed higher promoter activity compared to the pGL3-
basic reporter vector. Relative to the pGL3-basic reporter
vector, Luc128, Luc388, Luc532 and Luc1107 increased
luciferase activity 2-fold, 20-fold, 8-fold and 53-fold,
respectively (Fig. 6). These data suggest that there are pos-
itive regulatory elements in the regions from -1107 to -
532, -388 to -128 and from -128 to -48 upstream of Gli3
and negative regulatory elements in the region from -532
to -388 upstream of Gli3.
HoxD13 binding sites in the 5' region of the rat Gli3
To identify the transcription factors that directly regulate
Gli3 expression, we analyzed the genomic region
upstream of the transcription start site of the Gli3 gene
with the transcription binding-site prediction program P-
Match. Two putative HoxD13 binding sites, the HoxD13
binding site 1 (-667): gttct and the HoxD13 binding site 2
(-477):ctagg were identified, suggesting that Hoxd13
could directly bind to these sites to regulate Gli3 expres-
sion (Fig. 7).
To verify the in vivo binding of Hoxd13 to the Gli3 pro-
moter, we used ChIP. Cross-linked and sheared chroma-
tin from rat GD14 embryonic hindlimbs were
immunoprecipitated with an anti-Hoxd13 antibody and
analyzed by PCR. These ChIP analyses revealed that, in
vivo, Hoxd13 efficiently bound only to binding site 2 (Fig.
8). Additionally, nucleoprotein containing Hoxd13 was
incubated with a fragment of -483 ~ -446 bp upstream of
Gli3 containing site 2. As shown in Fig. 9, strong DNA
binding was observed in the presence of the Hoxd13 pro-
tein. A competition experiment and supershift existence
in the presence of the Hoxd13 antibody demonstrated the
specificity of such binding. The result indicated Hoxd13 is
bound to site 2 in vitro.
Discussion
The mammalian Gli gene family encodes zinc finger tran-
scription factors and plays a role in developmental regula-
tion and human diseases [34]. One member of this
family, Gli3, was identified as a candidate gene for ICTEV
[26]. To investigate the mechanism of this association, we
investigated Gli3 mRNA and protein expression patterns
in ICTEV patients. Gli3 was not expressed in the flexor hal-
lucis longus of ICTEV patients, suggesting that although
Real-time PCR analysis of Gli3 expression in the hindlimb of ICTEV model r t nd n rmal cont ol rat embryosFigure 3
Real-time PCR analysis of Gli3 expression in the hind-
limb of ICTEV model rat and normal control rat 
embryos. Compared to the normal control, Gli3 mRNA 
expression was significantly enhanced. With birth drawing 
near, Gli3 expression in both model and normal rats had the 
tendency to decrease. Column 1, 3, 5 and 7 show Gli3 rela-
tive expression in ICTEV model rat at GD15, GD17, GD19 
and GD21, respectively. Column 2, 4, 6 and 8 show Gli3 rela-
tive expression in normal control rat embryos at GD15, 
GD17, GD19 and GD21, respectively.
Western blot resultsFigure 4
Western blot results. Western blots were used to deter-
mine Gli3 protein abundance in nuclear extracts from the 
hindlimb tissue of ICTEV model rat and normal control rat 
embryos. Compared to the normal control, Gli3 expression 
was significantly enhanced in model rats. With birth drawing 
near, Gli3 protein expression in both model and normal rats 
had a tendency to decrease. Lane 1 is the protein of ICTEV 
model rat embryos at GD15, lane 2 is the protein of normal 
rat embryos at GD15, lane 3 is the protein of ICTEV model 
rat embryos at GD17 and lane 4 is the protein of normal rat 
embryos at GD17.Page 6 of 10
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longer expressed in postnatal limbs.
To investigate the role of Gli3 role in ICTEV earlier in
development, we established an ICTEV rat model and
detected Gli3 expression in rat embryonic hindlimbs.
There are some concerns regarding the rat model of ICTEV
induced with ATRA in pregnant rats. The rat model has
some limitations. After induction with ATRA, not all fetal
rats were exhibited with symptoms of ICTEV. Those that
developed the clubfoot also developed malformations
such as rima oculi, spina bifida, cranial deformation and
anal atresia. Although the rat model of ICTEV induced
with ATRA is not ideal and is controversial, it is currently
the best rat model of ICTEV. We tested different dosages
of ATRA in preliminary experiments and found that 135
mg/kg was the dose at which the highest percentage
(about 30%) of clubfeet in the lower limbs was achieved.
We only selected the fetal rats with clubfeet as the experi-
mental subjects to ensure the most legitimate comparison
to patients with ICTEV. We found that both Gli3 mRNA
and protein expression levels were higher in the ICTEV
model rats compared to normal control rats. Furthermore,
with birth drawing near, the Gli3 gene expression in both
of the normal control group and the model group was
gradually downregulated (Figs. 3 and 4), indicating that
the Gli3 gene is a very important gene in regulating the
limb development and that its role of regulating limb
development may disappear after birth. This is also con-
sistent the inability to detect the Gli3 gene in the flexor
hallucis longus of adults (Fig. 1), which may be because it
is not expressed in the lower limb post-birth. The occur-
rence of ICTEV may be caused by changes in the expres-
sion level of this critical gene that is related to limb
development. Immunohistochemical results suggest that
Gli3 protein expression in the muscles around ankles of
model fetal rats was remarkably higher than in the control
group, and the affected sites of patients with ICTEV were
also in the ankle. The location of this muscle was identical
to that of flexor hallucis longus; therefore, it is reasonable
to conclude that the occurrence of ICTEV is associated
Immunohistochemistry resultsFigure 5
Immunohistochemistry results. Immunohistochemistry revealed that Gli3 expression in the hindlimb tissue of ICTEV 
model rat embryos was higher than that in normal control rat embryos at GD19 (400×). (A) Hindlimb tissue of a normal con-
trol rat embryo labeled with PBS. (B) Hindlimb tissue of an ICTEV model rat embryo labeled with Gli3 antibody. (C) Hindlimb 
tissue of a normal control rat embryo labeled with Gli3 antibody.
Relative activities of rat Gli3 promoter regions in a luciferase report r onstructFigu e 6
Relative activities of rat Gli3 promoter regions in a 
luciferase reporter construct. Activities were measured 
in L6 cells. Findings suggested positive regulatory elements 
existed in the regions from -1107 to -532, -388 to -128 and 
from -128 to -48 upstream of Gli3 and negative regulatory 
elements in the region from -532 to -388 upstream of Gli3.Page 7 of 10
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Potential binding sitesFigure 7
Potential binding sites. The rat Gli3 proximal promoter region contains two potential HoxD13 binding sites (gray boxes). 
The transcription start site is indicated by an arrow. The Gli3 protein translation start site (ATG) is indicated.
ChIP resultsFigure 8
ChIP results. The ChIP assay of putative HoxD13 binding 
sites 1 and 2 in the Gli3 promoter. Only HoxD13 binding site 
2 binds HoxD13 in vivo. In lanes 1 and 5, chromatin from rat 
embryonic hindlimbs was immunoprecipitated with the 
HoxD13 antibody. In lanes 2 and 6, the Sox9 antibody was 
used as a negative control. Lanes 3 and 7 show the enzymatic 
shearing before immunoprecipitation. Genomic DNA was 
used as a positive control (lanes 4 and 8). Lane M is a size 
marker.
EMSA resultsFigure 9
EMSA results. Electrophoretic mobility shift assay (EMSA) 
using oligonucleotide probes containing the HoxD13 binding 
site 2. The *** denotes unbound biotin-labeled DNA, ** 
denotes Hoxd13-DNA complexes and * denotes Hoxd13-
antibody-Hoxd13-DNA complexes.
BMC Musculoskeletal Disorders 2009, 10:142 http://www.biomedcentral.com/1471-2474/10/142with changes in the expression level of Gli3. To identify
the underlying reason for the change in Gli3 expression,
we first looked for mutations in the GLI3 promoter and
coding regions of ICTEV patients. A previous study inves-
tigating mutations in GLI3 exons 9, 10, 11 and 12 identi-
fied only one polymorphism [26]. To complete this study,
we sequenced the remaining exons and the promotor, but
did not detect any polymorphisms. While a larger sample
size might reveal polymorphisms, these data suggest that
the Gli3 mutation is not the root of its association with
ICTEV.
The changes in Gli3 gene expression may be caused by
changes in some transcription factors that regulate the
GLI3 gene, ultimately leading to the development of
ICTEV. Accordingly, future studies should focus on the
regulation of the GLI3 gene and its function.
Alternatively, Gli3 could be differentially regulated in
ICTEV model rat embryos compared to normal control
embryos. To determine the transcription factors that bind
to the promoter region of Gli3, we constructed a series of
rat Gli3 truncated promoters and cloned them into
reporter gene constructs. These analyses suggested that the
promoter has both positive and negative regulatory ele-
ments. Putative HoxD13 binding sites 1 and 2 in Gli3's
upstream 5' region were located in positive and negative
regulatory elements, respectively. HoxD13, however, only
bound to site 2 in vivo. In vitro competition experiments
also revealed a specific affinity of Hoxd13 to this site.
Thus, Hoxd13 can directly regulate the expression of Gli3
during limb formation. We cannot, however, exclude the
possibility that Hoxd13 interacts with the Gli3 promoter
regions as a part of a protein complex. In ICTEV patients,
HOXD13 has lower expression compared to healthy sub-
jects [27]. Thus, the decrease in HOXD13 expression
maybe led to a change in the expression of GLI3, which
manifests as ICTEV.
This study provides a theoretical basis for the pathogene-
sis of ICTEV. Future studies will investigate how HoxD13
regulates Gli3 during limb development and will provide
a clearer mechanism for the pathogenesis of ICTEV.
Conclusion
Our study indicates that HoxD13 directly interacts with
the promoter of Gli3 and Gli3 mRNA and protein expres-
sion levels were increased in the ICTEV model rats. These
findings suggest that HoxD13 is a transcription factor of
Gli3. Low expression of HOXD13 might lead to increase
GLI3 expression level during limb formation, which likely
plays a key role in ICTEV pathogenesis.
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